From BioBridge Training 2 to the 2026 London Symposium

Following BioBridge Training 2 London on 4–5 June 2026, the next step in the UK educational pathway is becoming clearer. What began in London as a two-day programme combining a scientific forum and advanced hands-on training should now be understood as part of a broader effort to support sound, structured and reproducible medical training in regenerative medicine.

{

The June programme was designed for healthcare professionals and built around a progression from science to workflow. Public event material describes a structure centred on PRP physiology, HA+PRP microenvironment logic, fibrin / ATS rationale and device compliance, while the practical training translated those principles into specialty-specific reasoning across andrology, women’s health and dermal practice.

In content terms, the London pathway already reflects the main Regen Lab product families used in professional education.

RegenPRP™ supports the narrative around standardised leucocyte-reduced PRP and reproducible preparation. RegenPRP™ – HA / Cellular Matrix supports the logic of a cell-friendly HA-PRP network and a hydration-to-support continuum. RegenPRP™ + ATS supports the fibrin-based scaffold and structural logic that underpins gel and biofiller-style educational discussion. 

This is also why the London educational pathway matters for the UK context. The direction is not generic promotion. It is the development of evidence-aware and governance-led education around biological rationale, workflow discipline, documentation, patient communication and safe implementation in clinic.

RegenPRP™

Standardised leucocyte-reduced platelet concentrate; user-independent standardised preparation; safe closed-circuit system. 

RegenPRP™ - HA / Cellular Matrix

Closed-circuit preparation of a cell-friendly PRP-HA network; HA presented by Regen Lab as supporting matrix logic and hydration. 

RegenPRP™ + ATS

Physiological coagulation activation and fibrin-matrix formation for longer-lasting growth factor delivery and scaffold support. 

The next milestone is the BioBridge International Symposium planned for 18 September 2026 at the Royal Society of Medicine. Within that progression, the June London programme should now be read as the practical educational prelude, and the September symposium as the broader scientific and educational forum. 

Reference Links

BioBridge Training 2 London

***

BioBridge Knowledge Platform

***

BioBridge Foundation LinkedIn

***

UK 2026 Clinicians’ Webinar Series

***

About Us

Since 2003, Regen Lab SA has specialized in designing and manufacturing high-quality medical devices for cell therapies and the preparation of autologous platelet-rich plasma (PRP) from the patient's own blood for bedside procedures.

Milestones

2003 - Foundation
2010 - RegenKit first approval in bone graft
2013 - A new state-of-theart laboratory in Lausanne
2014 - Cellular Matrix first approval
2015 - Launch of Cellular Matrix in Europe

Vision

Founded in 2003, Regen Lab has become a global reference thanks to its commitment to innovation, quality, and the effectiveness of its therapeutic solutions. Here’s how we have transformed the medical landscape over the past two decades.

RegenPRP™

RegenPRP™ is a medical treatment that uses platelet-rich plasma from the patient's own blood to enhance and tissue regeneration.

RegenPRP™ - HA

RegenPRP™ - HA combination is an innovative treatment combining platelet-rich plasma (PRP) and hyaluronic acid to improve tissue regeneration and healing.

RegenPRP™ - ATS

RegenPRP™ combined with ATS (Autologous Thrombin Serum) is an advanced approach to tissue regeneration that uses autologous thrombin-enriched platelet-rich plasma (PRP) to maximise healing effects.

RegenExtracell®

RegenExtracell is an innovative tissue regeneration treatment using an extracellular matrix enriched with platelet-rich plasma (PRP).

RegenWound

RegenWound is a fully autologous solution prepared from the patient’s own blood, with the objective of providing a standardised and reproducible approach for clinical use.

Regulatory

Manufacturers of medical devices based outside the EU must designate an Authorized Representative (EU-REP) established within the EU in order to meet the CE requirements for placing medical devices on the EU market.

Quality Management

Regen Lab Quality System Management ensures the consistency of our products quality in total GMP compliance.

Our production facility rooms atmosphere is monitored to satisfy non-pyrogenic medical devices manufacturing.

Patents

As a leader in the PRP&HA regenerative field and as an innovation-driven company, Regen Lab SA has devoted important resources since 2004 to put on the market pioneering and diversified products constituting a complete set of tools/technologies for the medical community.